| Dr Micael Lopez-acevedo, MD | |
|
Calle Hernandez Carrion, Urb Atenas, Manati, PR 00674 | |
| (787) 621-4949 | |
| Not Available |
| Full Name | Dr Micael Lopez-acevedo |
|---|---|
| Gender | Male |
| Speciality | Gynecological Oncology |
| Experience | 16 Years |
| Location | Calle Hernandez Carrion, Manati, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396903415 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mogic Ob-gyn Psc | 3476804709 | 4 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.
SNM supports the U.S. Senate in its introduction of the Consistency, Accuracy, Responsibility and Excellence in Medical Imaging and Radiation Therapy Act of 2010, S. 3737. The proposed legislation, which was introduced in August by Sen. Mike Enzi [R-WY], aims to ensure that minimum education and credentialing standards for nuclear medicine technologists are set at the state level.
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.
Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).
A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).
› Verified 3 days ago
| Entity Name | Mogic Ob-gyn Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285928770 PECOS PAC ID: 3476804709 Enrollment ID: O20180925002636 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.
SNM supports the U.S. Senate in its introduction of the Consistency, Accuracy, Responsibility and Excellence in Medical Imaging and Radiation Therapy Act of 2010, S. 3737. The proposed legislation, which was introduced in August by Sen. Mike Enzi [R-WY], aims to ensure that minimum education and credentialing standards for nuclear medicine technologists are set at the state level.
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.
Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).
A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).
› Verified 3 days ago
| Entity Name | Centro De Cancer De La Universidad |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215418751 PECOS PAC ID: 7113220385 Enrollment ID: O20210318001999 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.
SNM supports the U.S. Senate in its introduction of the Consistency, Accuracy, Responsibility and Excellence in Medical Imaging and Radiation Therapy Act of 2010, S. 3737. The proposed legislation, which was introduced in August by Sen. Mike Enzi [R-WY], aims to ensure that minimum education and credentialing standards for nuclear medicine technologists are set at the state level.
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.
Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).
A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).
› Verified 3 days ago
| Entity Name | Puerto Rico Women And Children S Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689148298 PECOS PAC ID: 3476955329 Enrollment ID: O20211020001448 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.
SNM supports the U.S. Senate in its introduction of the Consistency, Accuracy, Responsibility and Excellence in Medical Imaging and Radiation Therapy Act of 2010, S. 3737. The proposed legislation, which was introduced in August by Sen. Mike Enzi [R-WY], aims to ensure that minimum education and credentialing standards for nuclear medicine technologists are set at the state level.
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.
Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).
A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Micael Lopez-acevedo, MD Po Box 1087, Manati, PR 00674 Ph: () - | Dr Micael Lopez-acevedo, MD Calle Hernandez Carrion, Urb Atenas, Manati, PR 00674 Ph: (787) 621-4949 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.
SNM supports the U.S. Senate in its introduction of the Consistency, Accuracy, Responsibility and Excellence in Medical Imaging and Radiation Therapy Act of 2010, S. 3737. The proposed legislation, which was introduced in August by Sen. Mike Enzi [R-WY], aims to ensure that minimum education and credentialing standards for nuclear medicine technologists are set at the state level.
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.
Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).
A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).
› Verified 3 days ago
Mr. Jose L Ortiz Colon, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Jp Reyes Lopez J-49 Urb Atenas, Manati, PR 00674 Phone: 787-854-3249 Fax: 787-854-2613 | |
Dr. Jorge A. Otero-quintana, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: Edificio Medico I Dr. Pedro Blanco Lugo, Carr. 2 Km. 47.7 Suite 305, Manati, PR 00674 Phone: 787-854-0800 Fax: 787-854-0808 | |
Dr. Carlos R. Baez - Marin, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: Doctors' Center Hospital, Medicina Especializada Bldg., Road #2 Km. 47.7, Manati, PR 00674 Phone: 787-621-3378 Fax: 787-621-3319 | |
Mr. Giovanni Gonzalez Sr., MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: Calle Elliot Velez B 42, Urbanizacion Atenas, Manati, PR 00674 Phone: 787-854-7531 Fax: 787-884-8753 | |
Dr. Aurelio Miro Rosado, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: Carr #2 Km 47.7, Manati, PR 00674 Phone: 787-621-3300 Fax: 787-813-1512 | |
Jorge E Silva, M.D, Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 112 Medical Office, Hernandez Carrion , Urb. Atenas, Manati, PR 00674 Phone: 787-854-8000 |